… and mesenchymal stem cells. Amputation rate was improved more in trials wherein the …
Cell therapy was not associated with severe adverse events. Remarkably, efficacy of cell therapy …

… in cardiovascular disease. … cells and MSCs for cardiac regenerative medicine, the source
of MSCs for clinical use and problems to consider when conducting clinical MSC therapy…

… infarction and heart failure. The most important conclusion relevant to heart disease is
that … with reperfusion (ischemia/reperfusion) and heart failure. While a role for apoptosis in …

… Multiple cell therapy approaches for heart disease have been tested in a clinical setting over
the years (Fig. 2). The first systematic efforts in cardiac regeneration, which occurred by the …

… Furthermore, patients with chronic ischemic heart disease have shown reduced function
of … clinical benefits from autologous cell therapy in patients with chronic disease. However, …

… blood mononuclear cells in patients with coronary and peripheral arterial disease. Phase I
… , 9 as well as in subjects with chronic ischemic heart disease. Thus far, the majority of these …

… The FOCUS-CCTRN trial is the first, to our knowledge, adequately powered study of cell
therapy in patients with chronic ischemic heart disease and LV dysfunction (LVEF ≤45%) to be …

… Thus, this mitochondrial method could potentially contribute to the safety of hiPSC-based
cell therapy for severe heart diseases, although high-speed flow cytometry of clinical grade is …

… in the ischemic heart can improve heart function by promoting … -210 may lead to a novel
therapy for ischemic heart disease. … activated cell sorting, we obtained 2 main populations of cells…

… sources, immediately captured the attention of clinicians confronted with patients who
suffer from disabling, life-threatening heart failure in acute or chronic ischemic heart disease. …